Bevacizumab and erlotinib first-line therapy in advanced non-squamous non-small-cell lung cancer (stage IIIB/IV) followed by platinum-based chemotherapy at disease progression. A multicenter phase II trial
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Carboplatin; Cisplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 May 2019 Biomarkers information updated
- 08 Jun 2012 Actual patient number is 104 as reported by ClinicalTrials.gov.
- 08 Jun 2012 Actual end date (1 Sep 2010) added aas reported by ClinicalTrials.gov.